Published in Clin Rheumatol on January 20, 2005
Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int (2005) 1.03
Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol (1992) 4.79
Arthritis induced by a T-lymphocyte clone that responds to Mycobacterium tuberculosis and to cartilage proteoglycans. Proc Natl Acad Sci U S A (1985) 3.31
Lines of T lymphocytes induce or vaccinate against autoimmune arthritis. Science (1983) 2.96
Bacillus Calmette-Guérin induced aseptic arthritis: an experimental model of reactive arthritis. J Rheumatol (1998) 2.59
Heat shock proteins as regulators of the immune response. Lancet (2003) 2.42
Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer. Clin Infect Dis (2000) 2.07
Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol (2001) 2.01
Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol (1986) 2.01
Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med (2000) 1.53
EXPERIMENTAL MODELS IN RHEUMATOID DISEASE. Arthritis Rheum (1964) 1.52
Autoantibodies in chronic pulmonary tuberculosis. J Chronic Dis (1970) 1.24
Atherosclerosis as an autoimmune disease: an update. Trends Immunol (2001) 1.20
Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy. Clin Exp Immunol (1995) 1.14
Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms. Clin Infect Dis (2000) 1.06
Monoclonal anti-tuberculosis antibodies react with DNA, and monoclonal anti-DNA autoantibodies react with Mycobacterium tuberculosis. Clin Exp Immunol (1986) 1.03
Crossrecognition by CD8 T cell receptor alpha beta cytotoxic T lymphocytes of peptides in the self and the mycobacterial hsp60 which share intermediate sequence homology. Eur J Immunol (1995) 0.95
Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology (1999) 0.91
Common epitopes between mycobacterial and certain host tissue antigens. Clin Exp Immunol (1985) 0.89
Common intra-articular T cell expansions in patients with reactive arthritis: identical beta-chain junctional sequences and cytotoxicity toward HLA-B27. J Immunol (1999) 0.85
Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig. J Urol (1992) 0.81
Polyarthritis as a complication of intravesical bacillus Calmette-Guerin immunotherapy for bladder cancer. Clin Rheumatol (1999) 0.80
Articular manifestations after the administration of intravesical BCG. Joint Bone Spine (2002) 0.79
Humoral immunity in chronic relapsing experimental autoimmune encephalomyelitis. The major oligoclonal IgG bands are antibodies to mycobacteria. J Neurol Sci (1982) 0.78
Clinical study of bladder cancer: Proteinuria as a predictor of recurrence and efficacy of intravesical bacille Calmette-Guerin therapy. Int J Urol (2004) 0.78
Intravesical Evans bacille Calmette-Guérin for carcinoma in situ of the urinary bladder. Scottish Urological Oncology Group. Br J Urol (1994) 0.78
Two cases of acute polyarthritis secondary to intravesical BCG adjuvant therapy for superficial bladder cancer. Clin Rheumatol (2002) 0.77
[Relapsing Reiter's syndrome after Bacillus Calmette-Guérin immunotherapy for bladder carcinoma]. Med Clin (Barc) (2003) 0.77
Sjögren's-like syndrome following intravesical bacillus Calmette-Guérin immunotherapy. Am J Med (2003) 0.77
Bcg and autoimmunity: another two-edged sword. J Autoimmun (2001) 0.76
Identification of a novel antibody associated with autoimmune pancreatitis. N Engl J Med (2009) 4.48
Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med (2013) 3.81
Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol (2012) 3.26
Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol (2005) 3.15
Tension-free midurethral slings in the treatment of female stress urinary incontinence: a systematic review and meta-analysis of randomized controlled trials of effectiveness. Eur Urol (2007) 3.14
Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol (2009) 3.14
Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol (2004) 3.06
Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. Eur Urol (2012) 2.84
Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol (2010) 2.82
Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol (2009) 2.76
Evidence for a cross-talk between human neutrophils and Th17 cells. Blood (2009) 2.75
Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur Urol (2012) 2.74
A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol (2008) 2.50
The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol (2011) 2.43
Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol (2008) 2.37
Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol (2007) 2.30
Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: A systematic review. Eur Urol (2006) 2.30
Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol (2008) 2.29
Impact of the learning curve on perioperative outcomes in patients who underwent robotic partial nephrectomy for parenchymal renal tumours. Eur Urol (2010) 2.21
Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol (2006) 2.15
Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer (2005) 2.15
Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol (2010) 2.11
Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol (2011) 2.10
Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol (2007) 2.09
N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatol Int (2007) 2.03
Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a critical review of outcomes reported by high-volume centers. J Endourol (2010) 2.00
Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int (2011) 1.85
Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma. J Urol (2009) 1.83
Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet (2011) 1.80
Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers. Cancer (2007) 1.79
Trans-rectal versus trans-perineal saturation rebiopsy of the prostate: is there a difference in cancer detection rate? Urology (2010) 1.77
A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol (2008) 1.77
Differential role of CD133 and CXCR4 in renal cell carcinoma. Cell Cycle (2010) 1.73
Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol (2007) 1.67
Interaction of antibodies against cytomegalovirus with heat-shock protein 60 in pathogenesis of atherosclerosis. Lancet (2003) 1.64
Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol (2010) 1.61
Effects of shock wave therapy in the skin of patients with progressive systemic sclerosis: a pilot study. Rheumatol Int (2010) 1.59
Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. Eur Urol (2010) 1.57
Factors predicting health-related quality of life recovery in patients undergoing surgical treatment for renal tumors: prospective evaluation using the RAND SF-36 Health Survey. Eur Urol (2009) 1.56
Independent predictors of metachronous bladder transitional cell carcinoma (TCC) after nephroureterectomy for TCC of the upper urinary tract. BJU Int (2008) 1.56
Complications and mortality after radical cystectomy for bladder transitional cell cancer. J Urol (2009) 1.53
Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol (2004) 1.52
Margin, ischemia, and complications (MIC) score in partial nephrectomy: a new system for evaluating achievement of optimal outcomes in nephron-sparing surgery. Eur Urol (2012) 1.50
Perioperative and renal functional outcomes of elective robot-assisted partial nephrectomy (RAPN) for renal tumours with high surgical complexity. BJU Int (2014) 1.48
Is simple enucleation a minimal partial nephrectomy responding to the EAU guidelines' recommendations? Eur Urol (2008) 1.45
Role of molecular markers in diagnosis and prognosis of renal cell carcinoma. Anal Quant Cytol Histol (2007) 1.45
International validation of the prognostic value of subclassification for AJCC stage pT3 upper tract urothelial carcinoma of the renal pelvis. BJU Int (2012) 1.41
In celiac disease, a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes. PLoS Med (2006) 1.34
Prospective evaluation with standardised criteria for postoperative complications after robotic-assisted laparoscopic radical prostatectomy. Eur Urol (2009) 1.32
Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature. Eur Urol (2010) 1.28
Relationship between age at diagnosis and clinicopathologic features of renal cell carcinoma. Eur Urol (2006) 1.27
A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum Mol Genet (2011) 1.24
Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol (2012) 1.21
Simple enucleation is equivalent to traditional partial nephrectomy for renal cell carcinoma: results of a nonrandomized, retrospective, comparative study. J Urol (2011) 1.19
Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. Hum Mol Genet (2012) 1.17
The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res (2010) 1.15
International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int (2010) 1.15
Prognostic factors in squamous cell carcinoma of the penis. Nat Clin Pract Urol (2007) 1.13
Magnetic resonance angiography findings of penile Mondor's disease. J Magn Reson Imaging (2009) 1.12
Primary lymphoma of the kidney. Report of a case and update of the literature. Arch Ital Urol Androl (2002) 1.12
Chromosomal gains in the sarcomatoid transformation of chromophobe renal cell carcinoma. Mod Pathol (2007) 1.12
Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol (2010) 1.11
Prognostic ability of simplified nuclear grading of renal cell carcinoma. Cancer (2007) 1.11
Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series. BJU Int (2011) 1.10
Does routine second transurethral resection affect the long-term outcome of patients with T1 bladder cancer? Why a flawed randomized controlled trial cannot address the issue. Eur Urol (2010) 1.10
Grading systems in renal cell carcinoma. J Urol (2007) 1.09
Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol (2009) 1.07
Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. J Urol (2010) 1.06
Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma. Mod Pathol (2007) 1.05
Cost-utility analysis of radical nephrectomy versus partial nephrectomy in the management of small renal masses: Adjusting for the burden of ensuing chronic kidney disease. Can Urol Assoc J (2013) 1.05
Nomogram predictive of cancer specific survival in patients undergoing partial or total amputation for squamous cell carcinoma of the penis. J Urol (2006) 1.05
Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. J Urol (2010) 1.04
Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int (2005) 1.03
Predicting the risk of bone metastasis in prostate cancer. Cancer Treat Rev (2013) 1.03
Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy. Can Urol Assoc J (2008) 1.03
Conditional survival predictions after nephrectomy for renal cell carcinoma. J Urol (2009) 1.02
Incidentally discovered adrenal myelolipoma. Report on 3 operated patients and update of the literature. Arch Ital Urol Androl (2002) 1.01
Learning curve and preliminary experience with da Vinci-assisted laparoscopic radical prostatectomy. Urol Int (2008) 1.00
Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. BJU Int (2013) 1.00
Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur Urol (2011) 1.00
Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort. BJU Int (2010) 0.99
Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol (2010) 0.99
Validation of the preoperative aspects and dimensions used for an anatomical (PADUA) score in a robot-assisted partial nephrectomy series. World J Urol (2011) 0.99
Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approach. PLoS Med (2005) 0.98
Unclassified renal cell carcinoma: an analysis of 85 cases. BJU Int (2007) 0.98
Multi-institutional validation of a symptom based classification for renal cell carcinoma. J Urol (2004) 0.98
Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur Urol (2007) 0.98
Chromophobe renal cell carcinoma: comprehensive analysis of 104 cases from multicenter European database. Urology (2005) 0.97
Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. BJU Int (2012) 0.96
Open versus laparoscopic partial nephrectomy for clinical T1a renal masses: a matched-pair comparison of 280 patients with TRIFECTA outcomes (RECORd Project). World J Urol (2013) 0.94
Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy. Cancer (2008) 0.94
A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. Hum Mol Genet (2013) 0.94